Ironwood Pharma (IRWD) Misses Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Ironwood Pharma (IRWD) Misses Q3 EPS by 21c

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

November 6, 2018 8:09 AM EST

LINZESS® (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017

Ironwood revenue of $66 million in 3Q 2018, which includes a $30 million reduction due to LINZESS change in estimate as reported to Ironwood by Allergan

Received Fast Track Designation for praliciguat for potential treatment of HFpEF

On track to complete separation of Ironwood into two independent, publicly traded companies in first half 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More